[1] 王端礼. 医学真菌学一实验室检验指南[M]. 北京:人民卫生出版社,2005:229-233. [2] Colombo AL, Padovan AC, Chaves GM. Current knowledge of Trichosporom spp. and trichosporonosis[J]. Clin Microbiol Rer, 2011, 24(4):682-700. [3] de Almeida Júnior JN,Hennequin C. Invasive Trichospooron infection:a systematic review on a re-emerging fungalpathogen[J]. Front Microbio1,2016,17 (7):629. [4] Montoya AM, Sanchez Gonzalez A, Palma-Nicolas JP, et al. Genotyping, extracellular compounds, and antifungal susceptibility testing of Trichosporon asahii isolated from Mexican patients[J]. Med Mycol, 2015, 53(5):505-511. [5] Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections[J]. Clin Microbiol Infect, 2014, 20(Suppl 3):76-98. [6] Kudo K, Teruik, Sasakis, et al. Voriconazole for both sucessful treatment of disseminated Trichosporon asahii infection and subsequent cord blood transplantation in an infant with acute myelogenous leukemia[J]. Bone Marrow Transplant, 2011, 46(2):310-311. [7] Ebright JR,Faiffax MR,Vazquez JA. Trichosporon asahii, a non-Candida yeast that caused fatal septic shock in a patient with outcancer or neutropenia[J]. Clin Infect Dis, 2001, 33(5):E28-30. [8] Toriumi Y, Sugita T, Nakajima M, et al. Antifungal pharmacodybamic characterisitics of amphotericin B against Trichoaporon asahii, using time-kill methodology[J]. Microbiol Immunol, 2002, 46(2):89-93. [9] 栗方,曹彬,刘颖梅,等. 阿萨希毛孢子菌感染的临床和药物敏感性分析[J]. 中华临床感染病杂志, 2010, 3(6):343-345. [10] 徐春晖,林青松,宿扬,等. 血液病患者合并阿萨希毛孢子菌菌血症3例并文献回顾[J]. 中国真菌学杂志, 2019, 14(2):104-106. |